



an Open Access Journal by MDPI

Challenges and Opportunities for Novel Therapeutic Strategies in Pediatric Oncology

Guest Editors:

Dr. Jeong A Park

Pediatric Hematology & Oncology, Department of Pediatrics, Inha University Hospital, Inha University College of Medicine, Incheon, Republic of Korea

Dr. Jaume Mora

Pediatric Oncologist, Scientific Director of the Pediatric Cancer Center Barcelona (PCCB), Barcelona, Spain

Deadline for manuscript submissions: **28 February 2026**



mdpi.com/si/172532

Message from the Guest Editors

Dear Colleagues,

The last decade has seen a revolution in our understanding of the molecular and genetic basis of pediatric cancers. Molecular and genetic characterization is being integrated into cancer diagnosis, revealing subgroups of pediatric cancers with both prognostic and therapeutic relevance. This enables risk-adoptive therapy, focusing intensive therapy on the most aggressive cancers while refining the treatment for low-risk diseases, resulting in a significant reduction in serious long-term complications.

Cancer immunotherapy changed the prognosis of high-risk malignancies. How to define which tumors are more likely to respond to immunotherapy and how to activate the immune system via either cell-based or antibody-based strategies remain major challenges.

This Special Issue will highlight the advances in our understanding of pediatric malignancies and in the development of treatments including small-moleculartargeted therapies, BsAb, CART, transplant, radioisotope, drug conjugates, radiotherapy, and photoimmunotherapy and address current challenges and future prospects for more personalized therapy for pediatric cancer.

Dr. Jeong A Park Dr. Jaume Mora *Guest Editors*







an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions. **High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase,

CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 www.mdpi.com mdpi.com/journal/cancers cancers@mdpi.com X@Cancers_MDPI